BrightGene Bio-medical Technology(SH:688166) Zheng Quan Zhi Xing·2025-06-09 13:31Group 1 - The company, BrightGene Bio-Medical Technology Co., Ltd., issued convertible bonds totaling RMB 465 million, with a net fundraising amount of RMB 456.83 million after deducting issuance costs [3][18]. - The bonds have a maturity period of six years, from January 4, 2022, to January 3, 2028, with a face value of RMB 100 per bond [3][4]. - The coupon rates for the bonds are structured to increase over the years, starting at 0.4% in the first year and reaching 3% in the sixth year [3][4]. Group 2 - The company reported a revenue of RMB 1.28 billion for the fiscal year 2024, representing an 8.74% increase from the previous year [17]. - The net profit attributable to shareholders decreased by 3.12% to RMB 180.51 million, primarily due to increased R&D expenses [17]. - The company’s total assets increased by 2.63% to RMB 5.16 billion, indicating stable growth in its financial position [17]. Group 3 - The company focuses on innovative pharmaceutical development, emphasizing original drugs and complex formulations to meet unmet clinical needs globally [15][16]. - Key therapeutic areas include antiviral, antifungal, immunosuppressive, respiratory, oncology, and metabolic diseases, with core products in each category [16]. - The company has a strong commitment to R&D, with R&D expenses increasing by 19.65% year-on-year, reflecting its strategy of being research-driven [17]. Group 4 - The bonds are rated AA- by Dongfang Jincheng International Credit Rating Co., Ltd., with a stable outlook, indicating a strong credit profile [5][21]. - The company has established a dedicated fund management system to ensure the proper use of raised funds, adhering to regulatory requirements [20]. - The company has not experienced any defaults on bond repayments, demonstrating a stable repayment capability [21].